Source comparison
BPC-157 Protocol Combat Sports: Evidence Comparison
Daily Dose 250–350mcg subcutaneous 400–500mcg subcutaneous Not recommended. Mechanism is localized Acute injuries respond to lower doses because inflammation hasn't yet degraded collagen matrix; chronic injuries need higher concentration to drive fibroblast ac
This comparison does not assign a generated winner or score.
- Daily Dose
- 250–350mcg subcutaneous
- 400–500mcg subcutaneous
- Not recommended. Mechanism is localized
- Acute injuries respond to lower doses because inflammation hasn't yet degraded collagen matrix; chronic injuries need higher concentration to drive fibroblast activity through scar tissue
- Injection Site
- Within 2cm of injury
- Within 3cm of injury, rotate sites
- N/A
- Proximity matters more for chronic injuries where scar tissue limits diffusion; acute injuries show response even at 3–4cm distance
- Cycle Length
- 4 weeks minimum
- 6–8 weeks
- Extending beyond 8 weeks shows diminishing returns in animal studies; assess structural recovery at week 6 before continuing
- Training Load Week 1–3
- 50–60% intensity, avoid injury-specific loading
- 40–50% intensity, focus on pain-free range of motion
- Chronic injuries require more cautious load progression because underlying tissue quality is already compromised
- Training Load Week 4–6
- 70–80% intensity, controlled sparring
- 60–70% intensity, gradual reintroduction
- The collagen crosslinking window is 4–6 weeks; premature full-intensity training before week 6 risks re-injury regardless of subjective pain reduction